| Issue | Title | |
| Vol 2023, No 6 (2023) | Novartis to acquire Chinook Therapeutics for US$3.2 B to Bolster Kidney Disease Portfolio | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2024, No 2 (2024) | Novartis to Acquire MorphoSys for US$2.9 B to Expand Oncology Pipeline | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2025, No 5 (2025) | Novartis to Acquire Regulus Therapeutics and Farabursen for US$1.7 B | Abstract pdf html |
| Naini Anand | ||
| Vol 2002, No 28 (2002) | Novartis to Acquire Slovenian Generics Company | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 66 (2005) | Novartis to Acquire the Remaining Stake in Chiron | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 80 (2007) | Novartis to Divest Medical Nutrition Business Unit to Nestlé | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | Novartis Validates Adimab’s Antibody Discovery Technology | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 53 (2004) | Novartis Validates Xenon and its Obesity Programme with US$157 M Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 86 (2007) | Novartis' Vaccine Boost | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 3 (2012) | Novartis’ Alcon Gains ex-US Rights to ThromboGenics’ Ocriplasmin | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 5 (2012) | Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 6 (2013) | Novo A/S Acquires Anti-Infectives Developer Xellia Pharmaceuticals from 3i | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 6 (2020) | Novo Nordisk Acquires Cardio-Renal Focused Corvidia Therapeutics | Abstract html pdf |
| Michelle Liu | ||
| Vol 2020, No 11 (2020) | Novo Nordisk Acquires Emisphere’s Eligen® Technology for US$1.8 B | Abstract pdf html |
| Michelle Liu | ||
| Vol 2003, No 36 (2003) | Novo Nordisk and Fournier Pharma Sign Co-Marketing Agreement for Repaglinide in Europe | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 7 (2021) | Novo Nordisk and Heartseed Enter into Agreement to Develop Cell therapy for Heart Failure | Abstract pdf html |
| Shikha Kashyap | ||
| Vol 2023, No 6 (2023) | Novo Nordisk and Life Edit Therapeutics Enter Gene Editing Collaboration in Rare and Cardiometabolic Diseases | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2008, No 93 (2008) | Novo Nordisk AS | Abstract |
| Business Review Editor | ||
| Vol 2018, No 8 (2018) | Novo Nordisk Joins the Pack with Smart-Insulin Acquisition of Ziylo for US$800 M | Abstract pdf html |
| Michelle Liu | ||
| Vol 2025, No 4 (2025) | Novo Nordisk Partners with The United Laboratories for US$2 B Cardiometabolic Drug Development | Abstract pdf html |
| Swati Sharan | ||
| Vol 2018, No 7 (2018) | Novo Nordisk Signs Diabetes and Obesity Collaboration with Kallyope | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2025, No 6 (2025) | Novo Nordisk Signs US$2.2B Licensing Pact with Septerna for Obesity | Abstract pdf html |
| Naini Anand | ||
| Vol 2024, No 2 (2024) | Novo Nordisk Signs US$252.6 M Deal with EraCal to Boost Obesity Portfolio | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2024, No 5 (2024) | Novo Nordisk Signs US$600 M Obesity Licensing Pact with Flagship’s Metaphore | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 9 (2022) | Novo Nordisk to Acquire Forma Therapeutics for US$1.1 B | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2023, No 10 (2023) | Novo Nordisk to Acquire Ocedurenone for Hypertension from KBP Biosciences | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2008, No 99 (2008) | Novosom Smarticles® to Encapsulate Isis Antisense Drugs | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2006, No 73 (2006) | Novozymes Acquires sanofi–aventis Subsidiary | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 71 (2006) | NOXXON Pharma AG | Abstract |
| Business Review Editor | ||
| Vol 2003, No 34 (2003) | NPS Pharmaceuticals and Enzon Pharmaceuticals Agree to Merger of Equals | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 4 (2013) | NPS Pharmaceuticals Regains Global Rights to Two Orphan Drugs from Takeda | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 54 (2004) | Nuvelo Acquires Alfimeprase Rights from Amgen | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 68 (2006) | Nuvelo: the Vindication of a Merger | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Nycomed and Micromet to Collaborate on Antibody Development | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 93 (2008) | Nycomed Finds Commercialisation Partner for Ciclesonide | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 89 (2007) | Nycomed Gains Rights to NPS’ Gattex™ | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 3 (2009) | Nycomed Looking for Buyers | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 91 (2008) | Oliver | Details jpg |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | OM Pharma to promote Gynazole-1 treatment in Latin America and Middle East | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 2 (2011) | Once-a-week | Abstract jpg |
| Clive Goddard | ||
| Vol 2011, No 1 (2011) | Oncolys Out-Licenses Phase II HIV Drug to Bristol-Myers Squibb | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 5 (2017) | OncoMed Forced to Regroup After Celgene-Partnered Drug Fails for a Second Time | Abstract pdf html |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | OncoMed Pharmaceuticals and Bayer Schering Pharma Sign a Global Cancer Pact Targeting the Wnt Pathway | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 83 (2007) | Ondeva (trimegestone) | Abstract pdf |
| Business Review Editor | ||
| Vol 2023, No 2 (2023) | Ono Pharmaceutical Acquires Multiple Research-Stage Oncology Programmes from KSQ Therapeutics | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2009, No 10 (2009) | Onyx Acquires Proteolix | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 8 (2010) | Onyx Pharmaceuticals Out-Licenses Japanese Rights to Proteasome Inhibitors | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 2 (2013) | Opexa Therapeutics Grants Merck Serono Option to Multiple Sclerosis T-cell Therapy | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 4 (2012) | Optimer Partners with Astellas Again to Commercialise Fidaxomicin in Japan | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | Orchid Buys Karalex Pharma for Generics Marketing Presence in the US | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 5 (2010) | Orchid in licensing deal with Alvogen | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 8 (2010) | Orexigen Finds Partner for Obesity Drug Prior to Regulatory Approval Decision | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 73 (2006) | Orexo AB | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 11 (2021) | Organon Advances Women’s Health Pipeline with US$954 M Forendo Acquisition | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2003, No 42 (2003) | Organon NV | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 10 (2024) | Organon to Acquire Dermavant Sciences for up to US$1.2 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2013, No 9 (2013) | Orphan Drug Developer Ultragenyx Licenses Kyowa Hakko Kirin’s X-Linked Hypophosphataemia Drug | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 42 (2003) | Orphan Medical Licenses Cataplexy Treatment to Celltech | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 56 (2005) | Ortho-McNeil's Re-Entry into the Diabetes Arena | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 28 (2002) | Oryx Pharmaceuticals to Market CNS Drugs in Canada | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Osei Acquires Exclusive Rights to Bacterial Therapeutic from Miyarisan | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | OSI Gains US Marketing Rights for Gelclair™ from Celgene | Abstract |
| Business Review Editor | ||
| Vol 2005, No 63 (2005) | OSI to Buy Eyetech for US$935 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 35 (2003) | OSI to Market Serono’s Novantrone® for Oncology Indications | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 7 (2018) | Otsuka Bolsters Pipeline with Acquisition of Antibody Developer Visterra | Abstract pdf html |
| Michelle Liu | ||
| Vol 2014, No 12 (2014) | Otsuka Continues Overseas Expansion with US$3.5 B Avanir Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 4 (2017) | Otsuka Gains Late-Stage ADHD Drug in Neurovance Acquisition | Abstract pdf html |
| Natasha Piper | ||
| Vol 2009, No 5 (2009) | Oxford BioMedica Handed Back Trovax® and Secures Ocular Disease Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2004, No 50 (2004) | Oxford BioMedica plc | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 9 (2009) | P&G Sells Pharma Division to Focus on Consumer Business | Abstract |
| Taskin Ahmed | ||
| Vol 2005, No 66 (2005) | Pain Therapeutics Reaps Late-stage Rewards | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | Palomar Issues Another Sublicence for Hair-removal Technologies | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 2 (2014) | Par Pharmaceutical Targets US Injectables Market with JHP Pharmaceuticals Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 9 (2011) | Par Pharmaceutical to Acquire Second Generics Company of 2011 | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 26 (2002) | Par Pharmaceutical to Market Three Rivers’ Ribavirin | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 37 (2003) | Partner Profile: CAMR | Abstract |
| Business Review Editor | ||
| Vol 2006, No 68 (2006) | Partnering | Details jpg |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | Partnering between Large Pharmas - Does it Make Sense? | Abstract |
| Business Review Editor | ||
| Vol 2007, No 89 (2007) | Passion and Determination are Success Drivers for Entrepreneurs | Abstract html |
| Fintan Walton | ||
| Vol 2008, No 93 (2008) | Patent | Details jpg |
| Business Review Editor | ||
| Vol 2008, No 93 (2008) | Patent Reform Could Threaten Innovation | Abstract html |
| Fintan Walton | ||
| Vol 2008, No 91 (2008) | Pay-for-Performance Deals | Abstract |
| Business Review Editor | ||
| Vol 2006, No 76 (2006) | Paying the Right Price in Biotech Acquisitions | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 83 (2007) | Paying Too Much? | Abstract html |
| Fintan Walton | ||
| Vol 2011, No 9 (2011) | PerkinElmer Agrees to Acquire Caliper Life Sciences for US$600 M | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 32 (2003) | Perlegen Enters into 3 Big Pharma Genomics Collaborations | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 1 (2013) | Pernix Therapeutics Agrees to Buy Beleaguered Somaxon Pharmaceuticals | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 11 (2012) | Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 8 (2013) | Perrigo Seeks Tax Advantages with Elan Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 11 (2014) | Perrigo to Become Top 5 OTC Player in Europe with US$4.5 B Omega Pharma Acquisition | Abstract |
| Heather Cartwright & Sayani Datta | ||
| Vol 2009, No 9 (2009) | Personalised Medicine – a Step Closer | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 8 (2010) | Pfizer Acquires FoldRx to Broaden its Orphan Drug Portfolio | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 12 (2021) | Pfizer Acquires Immuno-Inflammatory Company Arena for US$6.7 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2007, No 90 (2007) | Pfizer Acquires Immunology Company Coley | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 9 (2010) | Pfizer Acquires King and Expands Pain Management Portfolio | Abstract |
| Editorial Team | ||
| Vol 2019, No 5 (2019) | Pfizer Acquires Rare Disease Specialist Therachon | Abstract pdf html |
| Michelle Liu | ||
| Vol 2025, No 6 (2025) | Pfizer and 3SBio Forge US$6 B Oncology Alliance to Advance Bispecific Antibody Therapy | Abstract pdf html |
| Hitesh Udar | ||
| Vol 2012, No 8 (2012) | Pfizer and AstraZeneca Strike Global Agreement for OTC Version of Nexium® | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 8 (2011) | Pfizer and Qiagen Sign Second Companion Diagnostics Deal | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 92 (2008) | Pfizer and Tacere to Tackle HCV with RNAi Therapeutic | Abstract pdf |
| Business Review Editor | ||
| 1801 - 1900 of 2613 Items | << < 14 15 16 17 18 19 20 21 22 23 > >> | |